Preclinical evaluation of the antiproliferative potential of STI571 in Hodgkin's disease
2002
Evaluating STI571 for Hodgkin's Disease
Sample size: 20
publication
Evidence: low
Author Information
Author(s): Re D, Wickenhauser C, Ahmadi T, Buchdunger E, Kochanek M, Diehl V, Wolf J
Primary Institution: University of Cologne
Hypothesis
Can STI571 be an effective treatment for Hodgkin's disease?
Conclusion
Patients with Hodgkin's disease may not benefit from therapy with STI571.
Supporting Evidence
- Strong c-kit expression was detected in the Hodgkin and Reed Sternberg cell line L1236.
- Proliferation of L1236 cells was not affected by STI571.
- Twenty primary cases of classical Hodgkin's disease showed no c-kit expression.
Takeaway
The study looked at whether a drug called STI571 could help people with Hodgkin's disease, but it found that it probably won't work.
Methodology
The study analyzed cell lines and primary cases of Hodgkin's disease using immunohistochemistry and proliferation assays.
Limitations
The study was limited to a small number of cell lines and primary cases.
Participant Demographics
Twenty primary cases of classical Hodgkin's disease were analyzed.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website